Back Hepatitis C

Hepatitis C

CROI 2013: AbbVie Interferon-free Combos Cure Most Newly Treated Hepatitis C Patients

All-oral regimens containing the HCV protease inhibitor ABT-450, a non-nucleoside polymerase inhibitor, and ribavirin led to sustained response for more than 90% of previously untreated patients -- including those with unfavorable IL28B gene patterns -- but only about half of prior non-responders, researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.


Presidio and Boehringer Ingelheim Will Collaborate on Interferon-free Hepatitis C Combo

Presidio Pharmaceuticals and Boehringer Ingelheim will jointly conduct a Phase 2a trial to evaluate an all-oral combination containing its NS4A inhibitor PPI-668 plus faldaprevir and BI 207127, with or without ribavirin, for people with hard-to-treat genotype 1a hepatitis C virus.


CROI 2013: Progress in Hepatitis C Drug Development [VIDEO]

Hepatitis C and its treatment has been a key focus at the 20th Conference on Retroviruses and Opportunistic Infections(CROI 2013), taking place this week in Atlanta. Investigators gave an overview of their research and projections about forthcoming approvals of direct-acting antiviral agents at a morning press conference on Monday.


CROI 2013: Simeprevir and Faldaprevir Boost Interferon Response Rates for HIV/HCV Coinfected

Adding the hepatitis C virus (HCV) protease inhibitors simeprevir or faldaprevir to pegylated interferon plus ribavirin produces higher response rates and the potential for shorter treatment for HIV/HCV coinfected people, according to 2 studies presented last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.alt

CROI 2013: Sofosbuvir + Ledipasvir + Ribavirin Combo for HCV Produces 100% Sustained Response

An interferon-free regimen of the direct-acting hepatitis C drugs sofosbuvir (formerly GS-7997), ledipasvir (formerly GS-5885), and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive patients and prior non-responders with HCV genotype 1, according to data presented today at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.


CROI 2013: Simeprevir + Sofosbuvir Demonstrates Good Early Cure Rate With or Without Ribavirin

An all-oral combination of simeprevir plus sofosbuvir, with or without ribavirin, led to an early cure for most hard-to-treat prior null responders with genotype 1 hepatitis C studied in the Phase 2a COSMOS trial, according to a presentation at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.


Milk Thistle Drug May Help Control HCV Replication after Liver Transplant

Silibinin, a medication derived from the milk thistle plant, lowered hepatitis C virus (HCV) levels in patients awaiting liver transplantation in a pilot study, which may help reduce the risk of HCV recurrence in the new liver, Spanish researchers reported in the March 2013 Journal of Hepatology.


CROI 2013: French Studies Look at Telaprevir and Boceprevir for People with HIV/HCV Coinfection

Adding boceprevir or telaprevir to interferon-based therapy showed promising indications of efficacy and acceptable safety for difficult-to-treat HIV/HCV coinfected prior non-responders in a pair of French studies presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in this week in Atlanta.alt

NS5A Inhibitor Daclatasvir Has Dual Mode of Action Against Hepatitis C Virus

The promising investigational hepatitis C virus (HCV) NS5A inhibitor daclatasvir targets 2 steps of the viral replication process, enabling very rapid HCV RNA reduction, according to a mathematical model described in the February 19, 2013, advance edition of Proceedings of the National Academy of Sciences.